Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Lophora

Also known as: Lophora ApS

2 Drug Candidates

Lophora ApS is a Danish biotech developing next-generation selective 5-HT2A receptor agonists for psychiatric disorders. Their lead compound LPH-5, a novel cyclized phenethylamine, is in Phase 1 trials at Biotrial in Rennes, France. LPH-5 shows exceptional 5-HT2A selectivity and can produce antidepressant effects at sub-psychedelic doses. Secondary candidate LPH-48 is being explored for alcohol use disorder.

Drug Pipeline

2

LPH-5

Phase I
Treatment-Resistant Depression (TRD)

Cyclized phenethylamine (2C-X family), oral. Highly selective 5-HT2A agonist (Ki=1.3 nM). Phase 1 ongoing at Biotrial, Rennes. Low doses show antidepressant effects without full psychedelic experience.

LPH-48

Pre-clinical
Alcohol Use Disorder (AUD)

LPH-5 analog in preclinical development for alcohol use disorder.

Quick Facts

Type
Private Biotech
Founded
2018
Lead Stage
Phase I
Website
Visit